Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1. Patient Awareness of Need for Hepatitis A Vaccination (Prophylaxis) Before International Travel. Full Text available with Trip Pro

Patient Awareness of Need for Hepatitis A Vaccination (Prophylaxis) Before International Travel. Although hepatitis A virus (HAV) infection is preventable through vaccination, cases associated with international travel continue to occur. The purpose of this study was to examine the frequency of international travel and countries visited among persons infected with HAV and assess reasons why travelers had not received hepatitis A vaccine before traveling.Using data from sentinel surveillance (...) for HAV infection in seven US counties during 1996 to 2006, we examined the role of international travel in hepatitis A incidence and the reasons for patients not being vaccinated.Of 2,002 hepatitis A patients for whom travel history was available, 300 (15%) reported traveling outside of the United States. Compared to non-travelers, travelers were more likely to be female [odds ratio (OR) = 1.74 (95% confidence interval [95% CI], 1.35, 2.24)], aged 0 to 17 years [OR = 3.30 (1.83, 5.94)], Hispanic

2015 Journal of Travel Medicine

2. HIV, viral hepatitis and STIs - a guide for primary care

HIV, viral hepatitis and STIs - a guide for primary care HIV , VIRAL HEPATITIS & STIs SUPPOR TING THE HIV, VIR AL HEPATITIS AND SEXUAL HEALTH WORKFOR CE A GUIDE FOR PRIMARY CARE PROVIDERS HIV, VIRAL HEPATITIS & STIsHIV, VIRAL HEPATITIS AND STIs – A GUIDE FOR PRIMARY HEALTH CARE i HIV , VIRAL HEPATITIS & STIs SUPPOR TING THE HIV, VIRAL HEPATITIS AND SEXUAL HEALTH W ORKFOR CE A GUIDE FOR PRIMARY CAREii HIV, VIRAL HEPATITIS AND STIs – A GUIDE FOR PRIMARY HEALTH CAREHIV, VIRAL HEPATITIS AND STIs (...) – A GUIDE FOR PRIMARY HEALTH CARE iii HIV , VIRAL HEPATITIS & STIs A GUIDE FOR PRIMARY CARE 2014 EDITION EXPERT REFERENCE GROUP (EDITORIAL OVERSIGHT) Dr Michael Burke Nepean Sexual Health & HIV Clinic Ms Tracey Cabrie Victorian Infectious Diseases Service, Melbourne Health Associate Professor Ben Cowie Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, University of Melbourne Professor Greg Dore The Kirby Institute, UNSW Australia Dr Seamus Duffy Tuggerah Medical Centre Dr

2014 Clinical Practice Guidelines Portal

3. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) Kingdom Masoud Dara, World Health Organization (WHO) Regional Office for Europe, Denmark Michael Ninburg, World Hepatitis Alliance, United Kingdom Mika Salminen, National Institute for Health and Welfare, Finland Mojca Maticic, University Medical Centre Ljubljana, Slovenia Nikos Dedes, EATG/Positive Voice, Greece Peter Vickerman, University of Bristol, United Kingdom Philippa Easterbrook, WHO, Switzerland Raj Patel, IUSTI/NHS England, United Kingdom Ruta Kaupe, DIA+LOGS, Latvia Slim Fourati, European

2019 European Centre for Disease Prevention and Control - Public Health Guidance

4. CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults

CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults Can J Infect Dis Med Microbiol Vol 24 No 4 Winter 2013 217 CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults Mark Hull MD FRCPC 1 , Marina Klein MD FRCPC 2 , Stephen Shafran MD FRCPC 3 , Alice Tseng BScPhm PharmD FCSHP (...) 4 , Pierre Giguère BPharm MSc 5 , Pierre Côté MD 6 , Marc Poliquin MD 6 , Curtis Cooper MD FRCPC 7 ; on behalf of The CIHR Canadian HIV Trials Network HIV/Hepatitis C Management and Treatment Guidelines Working Group 1 University of British Columbia, British Columbia Centre for Excellent in HIV/AIDS, Vancouver, British Columbia; 2 McGill University, Montréal, Quebec; 3 University of Alberta, Edmonton, Alberta; 4 Toronto General Hospital, Toronto; 5 The Ottawa Hospital Research Institute, Ottawa

2014 CPG Infobase

5. Screening for hepatitis C

Screening for hepatitis C 1 Translation of the key statement of the final report S16-04 Screening auf Hepatitis C (Version 1.0; Status: 19 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-04 Screening for hepatitis C 1 Extract of final report S16-04 Version 1.0 (...) Screening for hepatitis C 19 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for hepatitis C Commissioning agency: Federal Joint Committee Commission awarded on: 22 September 2016 Internal Commission No.: S16-04 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Screening for Hepatitis C Virus: A Systematic Review

Screening for Hepatitis C Virus: A Systematic Review Screening for Hepatitis C Virus: A Systematic Review | CADTH.ca CADTH Document Viewer Screening for Hepatitis C Virus: A Systematic Review Table of Contents Search this document Screening for Hepatitis C Virus: A Systematic Review March 2017 Executive Summary The Issue The Canadian Task Force on Preventive Health Care (CTFPHC) requested a systematic review on screening for hepatitis C to help inform their recommendations. This systematic (...) review will be used along with other resources to develop the CTFPHC recommendations on screening for hepatitis C. 1 The scope of this review was developed with the CTFPHC. This report should not be interpreted as a stand-alone document, and readers are encouraged to consult the CTFPHC’s full guideline document. 2 Objectives The objectives are: (1) to assess the published research evidence on the clinical effectiveness, harms, cost-effectiveness, and associated patients’ preferences and values

2017 CADTH - Health Technology Assessment

7. Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer. Full Text available with Trip Pro

Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer. Antineoplastons are naturally occurring peptides and amino acid derivatives found in human blood and urine. Antineoplaston A10 and AS2-1 reportedly control neoplastic growth and do not significantly inhibit normal cell growth. Antineoplastons contain 3-phenylacetylamino-2, 6-piperidinedione (A10 (...) ), phenylacetylglutamine plus phenylacetylisoglutamine (A10-I), and phenylacetylglutamine plus phenylacetate (AS2-1). This open label, non- blinded randomized phase II study compared the efficacy of hepatic arterial infusion (HAI) with 5-fluorouracil,with or without antineoplastons as a postoperative therapy for colorectal metastasis to the liver.Sixty-five patients with histologically confirmed metastatic colon adenocarcinoma in liver, who had undergone hepatectomy, and/or thermal ablation for liver metastases were

2015 PloS one Controlled trial quality: uncertain

8. Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees

Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees Copyright © ESPGHAL and NASPGHAN. All rights reserved. Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees Lawrence J. Saubermann, y Mark Deneau, z Richard A. Falcone, § Karen F. Murray, jj Sabina Ali, Rohit Kohli (...) of the disease process, related to medication toxicity, or the result of an underlying primary hepatic disorder unrelated to IBD. This latter possibility is beyond the scope of this review article, but does need to be considered in anyone with elevated liver function tests. This review is provided as a clinical summary of some of the major hepatic issues that may occur in patients with IBD. KeyWords: autoimmune hepatitis, Crohn disease, hepatitis, in?ammatory bowel disease, primary sclerosing cholangitis

2017 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

9. Treatment of Hepatitis C

Treatment of Hepatitis C EASL Recommendations on Treatment of Hepatitis C 2018 q European Association for the Study of the Liver ? Summary Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the dis- ease, and because of developments in diagnostic (...) procedures and improvements in therapy and prevention. These European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards. 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Introduction Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. 1 The long-term natural history of HCV

2018 European Association for the Study of the Liver

10. Disorders of the Hepatic and Mesenteric Circulation Full Text available with Trip Pro

Disorders of the Hepatic and Mesenteric Circulation ACG Clinical Guideline: Disorders of the Hepatic and Mesente... : American Journal of Gastroenterology ')} You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800 (...) Abstract Disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries have important clinical consequences and may lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma. Although literature in the field of vascular liver disorders is scant, these disorders are common in clinical practice, and general practitioners, gastroenterologists, and hepatologists may benefit from expert guidance

2020 American College of Gastroenterology

11. Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the HBV Basics…

Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the HBV Basics… Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the Hep B Basics - Hepatitis B Foundation , Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the Hep B Basics Image courtesy of dream designs at FreeDigitalPhotos.net If you’ve just been diagnosed with hepatitis B after a routine blood test or following a , you may be feeling overwhelmed with information about this complicated infection (...) and references to hepatitis B. Here is an explanation of these two terms and what happens when you’re first infected with the hepatitis B virus (HBV). Hepatitis B is transmitted through blood and body fluids. It can be spread during unprotected sex, unsafe medical procedures, exposure to blood that enters your body through a cut, or by sharing personal items such as body jewelry or toothbrushes. Most commonly it is spread during childbirth when the mother is infected. What is a ? When we’re infected

2016 hepbblog

12. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection

Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION UPDATED VERSION APRIL 2016 GUIDELINESGUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION UPDATED VERSION APRIL 2016 GUIDELINESWHO Library Cataloguing-in-Publication Data Guidelines for the screening care and treatment of persons with chronic hepatitis C infection (...) for alcohol use and counselling to reduce moderate and high levels of alcohol intake 50 6.2 Assessing the degree of liver fibrosis and cirrhosis 54 CONTENTS4 7. RECOMMENDATIONS ON TREATMENT 59 7.1 Assessment for HCV treatment 59 7.2 Treatment with direct-acting antiviral agents 62 7.3 Removal of recommendation for treatment with telaprevir or boceprevir 69 7.4 Preferred and alternative regimens for the treatment of persons with chronic hepatitis C virus infection 71 7.5 Treatment with pegylated interferon

2016 World Health Organisation Guidelines

13. Hepatitis C

Hepatitis C Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading

2018 Trip Evidence Maps

14. AASLD Guidelines for Treatment of Chronic Hepatitis B

AASLD Guidelines for Treatment of Chronic Hepatitis B Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance Norah A. Terrault, 1 Anna S.F. Lok, 2 Brian J. McMahon, 3 Kyong-Mi Chang, 4 Jessica P. Hwang, 5 Maureen M. Jonas, 6 Robert S. Brown Jr., 7 Natalie H. Bzowej, 8 and John B. Wong 9 Purpose and Scope of the Guidance This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic (...) Hepatitis B (1) and update the previous hepatitis B virus (HBV) guidelines from 2009. The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coin- fections, acute

2020 American Association for the Study of Liver Diseases

15. Infants born to hepatitis B-infected mothers: immunoglobulin policy

Infants born to hepatitis B-infected mothers: immunoglobulin policy Infants born to hepatitis B-infected mothers: immunoglobulin policy - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Infants born to hepatitis B-infected mothers: immunoglobulin policy Policy on the use (...) of passive immunisation with hepatitis B immunoglobulin (HBIG) for infants born to hepatitis B infected mothers. Published 12 August 2008 Last updated 17 January 2020 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document summarises the policy and evidence for passive immunisation

2020 Public Health England

16. Toolkit to support the generation of robust estimates of hepatitis C prevalence

Toolkit to support the generation of robust estimates of hepatitis C prevalence TECHNICAL REPORT Technical protocol for hepatitis C prevalence surveys in the general population SPHERE-C Project www.ecdc.europa.euECDC TECHNICAL REPORT Technical protocol for hepatitis C prevalence surveys in the general population SPHERE-C Project ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Erika Duffell and Andrew Amato-Gauci, and produced (...) : European Centre for Disease Prevention and Control. Technical protocol for hepatitis C prevalence surveys in the general population. Stockholm: ECDC; 2020. Stockholm, February 2020 ISBN 978-92-9498-423-4 doi: 10.2900/30190 Catalogue number TQ-03-19-928-EN-N © European Centre for Disease Prevention and Control, 2019 Cover picture: © Science Photo Reproduction is authorised, provided the source is acknowledged. For any use or reproduction of photos or other material that is not under the EU copyright

2020 European Centre for Disease Prevention and Control - Technical Guidance

17. Diagnosis and Management of Hepatitis C Infection in Infants, Children, and Adolescents

Diagnosis and Management of Hepatitis C Infection in Infants, Children, and Adolescents Copyright 2012 by ESPGHAN and NASPGHAN. Unauthorized reproduction of this article is prohibited. NASPGHAN Practice Guidelines: Diagnosis and Management of Hepatitis C Infection in Infants, Children, and Adolescents Cara L. Mack, y Regino P. Gonzalez-Peralta, z Nitika Gupta, § Daniel Leung, Michael R. Narkewicz, jj Eve A. Roberts, Philip Rosenthal, and # Kathleen B. Schwarz ABSTRACT Hepatitis C virus (HCV (...) , there are now several treatment options for children with chronic hepatitis C infection and many new therapies on the horizon. As a con- sequence, the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition brought together experts in pediatric hepatology to review the available data in children and provide clinicians with approaches to the diagnosis, management, and prevention of HCV infection in children and adolescents. The guideline details the epidemiology and natural history

2012 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

18. Hepatitis C

Hepatitis C WGO Global Guidelines Hepatitis C (long version) 1 World Gastroenterology Organisation Global Guidelines Diagnosis, Management, and Prevention of Hepatitis C 2017 Update Review Team Muhammad Umar (Chair, Pakistan), Aamir G. Khan (Co-chair, Pakistan) Zaigham Abbas (Pakistan), Sanjeev Arora (India), Naqvi Asifabbas (UK), Andre Elewaut (Belgium), Gamal Esmat (Egypt), Graham Foster (UK), Michael Fried (Switzerland), Khean-L Goh (Malaysia), Hamama Tul Bushra Khaar (Pakistan), Tayyab (...) & Professor of Medicine; Rawalpindi Medical College Rawalpindi Pakistan; Chief Gastroenterology & Hepatology Division; Clinical Coordinator of Hepatitis Prevention and Control Program; Holy Family Hospital Rawalpindi Pakistan; Ex-Governor, American College of Gastroenterology (ACG); Chairman AsiaHep Pakistan; Past President Pakistan Society of Gastroenterology; Past President Pakistan Society of Hepatology; President Rawalians’ Research Forum © World Gastroenterology Organisation, 2017 WGO Global

2017 World Gastroenterology Organisation

19. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy? (Abstract)

Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy? To compare the efficacy of lactulose plus rifaximin with efficacy of lactulose alone in the treatment of hepatic encephalopathy.A randomized controlled trial.Department of Medicine, Jinnah Hospital, Lahore, from December 2014 to June 2015.All patients who presented with hepatic encephalopathy due to decompensated chronic liver disease were randomly divided into two groups of 65 patients each (...) . One group was given 30 ml thrice daily lactulose alone and the other lactulose plus rifaximin 550 mg twice daily for 10 days. Informed consents were taken from the participants' attendants. Grades II-IV hepatic encephalopathy was noted according to West-Haven Classification. All subjects were followed until 10 days after admission.The mean age of patients was 56.06 +11.2 years, among which 46.9% were females and 53.1% were males. After ten days of follow-up, reversal was seen in 58.46

2018 Journal of the College of Physicians and Surgeons--Pakistan : JCPSP Controlled trial quality: uncertain

20. Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA ? addressing the vulnerable populations

Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA ? addressing the vulnerable populations SCIENTIFIC ADVICE Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations www.ecdc.europa.euECDC SCIENTIFIC ADVICE Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations ii This report (...) was commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Otilia Mårdh and Tarik Derrough, with additional input from Andrew Amato-Gauci and Helena de Carvahlo- Gomes. It was written by Carita Savolainen-Kopra, Mia Kontio, Jukka Lindeman, Jaana Isojärvi, Kirsi Liitsola and Marjukka Mäkelä from THL Finland and revised by ECDC. This guidance draws on several literature reviews and a survey entitled ‘Antenatal screening for HIV, hepatitis B, syphilis and rubella

2017 European Centre for Disease Prevention and Control - Public Health Guidance